BRAF and melanoma: Currently, the standard of care for the treatment of BRAF V600E-mutant melanoma includes a combination of vemurafenib (RAFi) plus cobimetinib (MEKi) plus atezolizumab (anti-PD-L1 mAb; Table 1) [49].